Free tool
FAERS Monitor: Humalog Kwikpen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 205747 or its brand name (Humalog Kwikpen, Insulin Lispro Recombinant). Reports on generic versions are filed under their own applications.
Reports
127,036
Serious
60,392
48% of reports
Hospitalization
32,435
Death reported
5,735
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased35,855
- incorrect dose administered8,446
- blood glucose decreased8,255
- drug ineffective7,655
- visual impairment5,017
- nausea4,777
- malaise3,727
- fatigue3,668
- hypoglycaemia3,662
- fall3,334
- drug dose omission3,313
- diarrhoea3,165
- vomiting3,165
- dyspnoea3,027
- pain3,020
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,188 |
| 2005 | 1,265 |
| 2006 | 1,680 |
| 2007 | 1,554 |
| 2008 | 1,463 |
| 2009 | 1,792 |
| 2010 | 1,841 |
| 2011 | 2,034 |
| 2012 | 2,106 |
| 2013 | 1,712 |
| 2014 | 4,564 |
| 2015 | 24,743 |
| 2016 | 8,420 |
| 2017 | 8,456 |
| 2018 | 8,846 |
| 2019 | 8,869 |
| 2020 | 9,074 |
| 2021 | 7,658 |
| 2022 | 6,679 |
| 2023 | 5,810 |
| 2024 | 5,439 |
| 2025 | 7,926 |
| 2026 | 3,917 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,927,123 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose increasedSignal | 35,855 | 38.7 | 38.3 | 1,075,173 |
| blood glucose decreasedSignal | 8,255 | 34.2 | 33.4 | 220,536 |
| hypoglycaemiaSignal | 3,662 | 13.4 | 13.0 | 39,059 |
| visual impairmentSignal | 5,017 | 6.9 | 6.8 | 24,631 |
| incorrect dose administeredSignal | 8,446 | 6.3 | 6.2 | 36,842 |
| drug dose omissionSignal | 3,313 | 3.4 | 3.3 | 5,439 |
| fall | 3,334 | 1.7 | 1.6 | 891 |
| malaise | 3,727 | 1.4 | 1.4 | 450 |
| vomiting | 3,165 | 1.1 | 1.1 | 38 |
| nausea | 4,777 | 1.0 | 1.0 | 0 |
| drug ineffective | 7,655 | 1.0 | 0.9 | 13 |
| dyspnoea | 3,027 | 0.9 | 0.9 | 46 |
| pain | 3,020 | 0.8 | 0.8 | 133 |
| diarrhoea | 3,165 | 0.8 | 0.8 | 143 |
| fatigue | 3,668 | 0.8 | 0.8 | 237 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.